1. Home
  2. BBSI vs ERAS Comparison

BBSI vs ERAS Comparison

Compare BBSI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barrett Business Services Inc.

BBSI

Barrett Business Services Inc.

HOLD

Current Price

$38.14

Market Cap

887.4M

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$6.62

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBSI
ERAS
Founded
1965
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
887.4M
1.0B
IPO Year
1993
2021

Fundamental Metrics

Financial Performance
Metric
BBSI
ERAS
Price
$38.14
$6.62
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$45.50
$3.88
AVG Volume (30 Days)
161.5K
5.4M
Earning Date
02-25-2026
11-12-2025
Dividend Yield
0.85%
N/A
EPS Growth
10.03
N/A
EPS
2.08
N/A
Revenue
$1,223,992,000.00
N/A
Revenue This Year
$10.70
N/A
Revenue Next Year
$7.58
N/A
P/E Ratio
$18.17
N/A
Revenue Growth
9.64
N/A
52 Week Low
$33.01
$1.01
52 Week High
$49.65
$6.49

Technical Indicators

Market Signals
Indicator
BBSI
ERAS
Relative Strength Index (RSI) 62.93 87.88
Support Level $36.73 $3.36
Resistance Level $37.47 $6.49
Average True Range (ATR) 0.81 0.62
MACD 0.23 0.28
Stochastic Oscillator 91.62 97.31

Price Performance

Historical Comparison
BBSI
ERAS

About BBSI Barrett Business Services Inc.

Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: